XML 51 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Oct. 29, 2023
Oct. 30, 2022
Cash flows from operating activities:    
Net (loss) income $ (449,672) $ 112,387
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:    
Depreciation and amortization 69,104 22,321
Amortization of right-of-use assets 4,954 3,475
Investment impairments and credit loss reserves, net 2,250 (376)
Accretion of deferred financing costs 4,940 520
Write-off of deferred financing costs 4,446 0
Deferred income taxes 56,355 2,383
Share-based compensation 28,341 27,228
Gain on disposition of business operations and assets (259) (18,256)
Equity method loss (income) 30 (271)
Corporate-owned life insurance, net 2,797 23
Goodwill impairment 281,821 0
Amortization of inventory step-up 3,314 0
Changes in assets and liabilities:    
Accounts receivable, net 5,016 (9,032)
Inventories 41,631 (3,470)
Other assets (13,203) 4,170
Accounts payable (33,768) (3,430)
Accrued liabilities (109,127) 12,127
Other liabilities (6,809) (4,289)
Net cash (used in) provided by operating activities (107,839) 145,510
Cash flows from investing activities:    
Proceeds from sales of property, plant and equipment 408 33
Purchase of property, plant and equipment (27,473) (22,643)
Proceeds from sale of investments 0 2,275
Purchase of investments (930) (6,748)
Purchase of intangibles (771) 0
Proceeds from sale of business, net of cash disposed 0 26,322
Proceeds from corporate-owned life insurance 2,500 5,065
Premiums paid for corporate-owned life insurance 0 (5,065)
Net cash used in investing activities (26,266) (761)
Cash flows from financing activities:    
Proceeds from revolving line of credit 70,000 10,000
Payments of revolving line of credit 0 (33,000)
Payments of term loans (272,375) 0
Proceeds from convertible senior notes 250,000 319,500
Proceeds from sale of warrants 0 42,909
Purchase of convertible note hedge 0 (72,559)
Deferred financing costs (17,812) (10,253)
Payments for employee share-based compensation payroll taxes (5,476) (13,766)
Proceeds from exercise of stock options 0 620
Repurchase of common stock 0 (50,000)
Net cash provided by financing activities 24,337 193,451
Effect of foreign exchange rate changes on cash and cash equivalents (1,922) 0
Net (decrease) increase in cash and cash equivalents (111,690) 338,200
Cash and cash equivalents at beginning of period 235,510 279,601
Cash and cash equivalents at end of period 123,820 617,801
Supplemental disclosure of cash flow information:    
Interest paid 63,525 10,267
Income taxes paid 19,655 8,749
Non-cash investing and financing activities:    
Accounts payable related to capital expenditures 281 3,803
Accrued deferred financing costs 8,418 3,330
Conversion of notes into equity $ 1,271 $ 0